Trinity Legacy Partners LLC Has $5.20 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Trinity Legacy Partners LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,457 shares of the company’s stock after buying an additional 598 shares during the period. Johnson & Johnson makes up about 2.1% of Trinity Legacy Partners LLC’s holdings, making the stock its 17th biggest position. Trinity Legacy Partners LLC’s holdings in Johnson & Johnson were worth $5,204,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its position in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P grew its stake in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its stake in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. grew its stake in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its stake in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 1.1 %

Johnson & Johnson stock opened at $152.38 on Friday. The business has a 50 day moving average price of $161.97 and a two-hundred day moving average price of $167.88. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The stock has a market cap of $396.84 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. Johnson & Johnson has a 12 month low of $150.71 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.13 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Piper Sandler lowered their target price on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Citigroup upped their price target on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. SVB Leerink decreased their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Finally, Atlantic Securities upped their price target on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.